Satio Unveils Innovative Intradermal Drug Delivery System
Satio, Inc. is excited to announce the successful development of a revolutionary intradermal drug delivery device named SatioRx. This advanced technology has been crafted with patient needs in mind, specifically targeting the managed delivery of liquid medications via a hollow microneedle (HMN) array. SatioRx represents a transformative approach by combining a reusable motor-driven applicator with an economical disposable component designed for ease of use.
Transforming Medication Delivery
The innovative SatioRx system incorporates a standard drug cartridge, an adhesive patch, and an array of microneedles, all paired with a Go/No-go pressure sensor and an NFC antenna. This configuration allows for versatile drug delivery, accommodating volumes ranging from 1mL to 5mL. With the ability to adjust the delivery of various drug types for viscosities as high as 100cP, this system addresses the limitations frequently encountered with traditional autoinjectors, which are typically thrown away after a single use.
Enhancing Patient Experience
Considering patient experience is a priority, particularly for those with chronic diseases requiring frequent injections, the design of this device streamlines administration. The SatioRx project embraces three promising approaches: a remote injection mechanism to eliminate the need for travel, a reusable device to enhance sustainability, and a microneedle delivery method to ease the discomfort of injections. This combination works to alleviate anxiety associated with needles while facilitating faster and more efficient medication delivery.
Healthcare providers can utilize this innovative system to administer precise drug dosages remotely while closely monitoring patients’ vital signs through a specialized software interface. This could significantly enhance the oversight of patients in rural areas who face challenges accessing frequent healthcare.
Achieving Milestones in Healthcare Innovation
The project's timeline saw completion within 18 months, culminating in thorough testing and successful trials involving live subjects. Achievements included short-run manufacturing, strategic meetings with FDA representatives regarding future applications, and establishing several letters of intent, reinforcing Satio’s commitment to delivering medical advancements.
Namal Nawana, the Executive Chairman and Founder of Satio, expressed gratitude for the support received throughout this endeavor. He highlighted that two groundbreaking accomplishments were achieved: remotely controlled drug delivery and the automation of intradermal administration. These milestones reflect Satio’s ongoing commitment to decentralize care and improve treatment options for chronic disease sufferers.
Addressing Self-Administration Challenges
The growing demand for at-home medication administration is underscored by the complexity inherent in modern biologics, which often complicates self-administration. The SatioRx device tackles these challenges head-on with its sophisticated design and comprehensive telehealth experience. These features are crafted to shift the patient's care site, ensuring that medications are delivered efficiently and with minimal discomfort.
By marrying cutting-edge technology with healthcare needs, the SatioRx device promises to enhance the quality of life for patients requiring regular drug delivery across various medical fields, including cardiometabolic health, immunotherapy, oncology, and autoimmune conditions.
Looking to the future, the precision automation utilized in delivering drugs directly into the intradermal skin could soon revolutionize at-home therapeutic applications, bridging the gap between drug developers and patients effectively.
These innovative solutions are not yet approved for sale within the US or in other territories.
About Satio, Inc.
Satio, Inc. is committed to revolutionizing healthcare through the advancement of its technologies, focusing on streamlined patient-provider interactions, enhanced diagnostics, and medicine delivery. A privately held medical device company, Satio strives to develop multiple platforms that include a reusable drug delivery system aimed at stable intradermal and subcutaneous administration of liquid medications, alongside innovative diagnostic tools for expansive blood testing applications.
Additionally, Satio is welcoming inquiries and communication about its endeavors and can be contacted for more details about their ongoing projects.
Frequently Asked Questions
What is the SatioRx device?
The SatioRx device is an intradermal drug delivery system designed to provide stable and controlled administration of liquid medications through microneedles.
How does SatioRx improve patient care?
SatioRx enhances patient care by allowing for remote administration of medications, reducing the need for travel, and offering a more comfortable injection experience.
What are the key features of the SatioRx system?
Key features include a reusable applicator, disposable cartridges, and the capability to handle varying drug volumes and viscosities.
What conditions can the SatioRx device address?
The device aims to assist patients with chronic conditions that require frequent medication delivery, including cardiometabolic and autoimmune diseases.
Is the SatioRx device currently available for sale?
Currently, the SatioRx device is not approved for sale in the US or other territories.
